Literature DB >> 25013067

Immunologic strategies for HIV-1 remission and eradication.

Dan H Barouch1, Steven G Deeks2.   

Abstract

Antiretroviral therapy (ART) is able to suppress HIV-1 replication indefinitely in individuals who have access to these medications, are able to tolerate these drugs, and are motivated to take them daily for life. However, ART is not curative. HIV-1 persists indefinitely during ART as quiescent integrated DNA within memory CD4(+) T cells and perhaps other long-lived cellular reservoirs. In this Review, we discuss the role of the immune system in the establishment and maintenance of the latent HIV-1 reservoir. A detailed understanding of how the host immune system shapes the size and distribution of the viral reservoir should lead to the development of a new generation of immune-based therapeutics, which may eventually contribute to a curative intervention.
Copyright © 2014, American Association for the Advancement of Science.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25013067      PMCID: PMC4096716          DOI: 10.1126/science.1255512

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  94 in total

1.  Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia.

Authors:  Masashi Shingai; Yoshiaki Nishimura; Florian Klein; Hugo Mouquet; Olivia K Donau; Ronald Plishka; Alicia Buckler-White; Michael Seaman; Michael Piatak; Jeffrey D Lifson; Dimiter S Dimitrov; Michel C Nussenzweig; Malcolm A Martin
Journal:  Nature       Date:  2013-10-30       Impact factor: 49.962

Review 2.  Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs.

Authors:  Christine Katlama; Steven G Deeks; Brigitte Autran; Javier Martinez-Picado; Jan van Lunzen; Christine Rouzioux; Michael Miller; Stefano Vella; Joern E Schmitz; Jeffrey Ahlers; Douglas D Richman; Rafick P Sekaly
Journal:  Lancet       Date:  2013-03-29       Impact factor: 79.321

3.  Absence of detectable HIV-1 viremia after treatment cessation in an infant.

Authors:  Deborah Persaud; Hannah Gay; Carrie Ziemniak; Ya Hui Chen; Michael Piatak; Tae-Wook Chun; Matthew Strain; Douglas Richman; Katherine Luzuriaga
Journal:  N Engl J Med       Date:  2013-10-23       Impact factor: 91.245

4.  Positive selection of mC46-expressing CD4+ T cells and maintenance of virus specific immunity in a primate AIDS model.

Authors:  Patrick M Younan; Patricia Polacino; John P Kowalski; Christopher W Peterson; Nicholas J Maurice; Nathaniel P Williams; On Ho; Grant D Trobridge; Dorothee Von Laer; Martin Prlic; Brian C Beard; Stephen DeRosa; Shiu-Lok Hu; Hans-Peter Kiem
Journal:  Blood       Date:  2013-05-29       Impact factor: 22.113

Review 5.  Immune activation and HIV persistence: implications for curative approaches to HIV infection.

Authors:  Nichole R Klatt; Nicolas Chomont; Daniel C Douek; Steven G Deeks
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988

6.  Cell-based measures of viral persistence are associated with immune activation and programmed cell death protein 1 (PD-1)-expressing CD4+ T cells.

Authors:  Hiroyu Hatano; Vivek Jain; Peter W Hunt; Tzong-Hae Lee; Elizabeth Sinclair; Tri D Do; Rebecca Hoh; Jeffrey N Martin; Joseph M McCune; Frederick Hecht; Michael P Busch; Steven G Deeks
Journal:  J Infect Dis       Date:  2012-10-22       Impact factor: 5.226

7.  Systemic effects of inflammation on health during chronic HIV infection.

Authors:  Steven G Deeks; Russell Tracy; Daniel C Douek
Journal:  Immunity       Date:  2013-10-17       Impact factor: 31.745

8.  Immune clearance of highly pathogenic SIV infection.

Authors:  Scott G Hansen; Michael Piatak; Abigail B Ventura; Colette M Hughes; Roxanne M Gilbride; Julia C Ford; Kelli Oswald; Rebecca Shoemaker; Yuan Li; Matthew S Lewis; Awbrey N Gilliam; Guangwu Xu; Nathan Whizin; Benjamin J Burwitz; Shannon L Planer; John M Turner; Alfred W Legasse; Michael K Axthelm; Jay A Nelson; Klaus Früh; Jonah B Sacha; Jacob D Estes; Brandon F Keele; Paul T Edlefsen; Jeffrey D Lifson; Louis J Picker
Journal:  Nature       Date:  2013-09-11       Impact factor: 49.962

9.  Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys.

Authors:  Dan H Barouch; James B Whitney; Brian Moldt; Florian Klein; Thiago Y Oliveira; Jinyan Liu; Kathryn E Stephenson; Hui-Wen Chang; Karthik Shekhar; Sanjana Gupta; Joseph P Nkolola; Michael S Seaman; Kaitlin M Smith; Erica N Borducchi; Crystal Cabral; Jeffrey Y Smith; Stephen Blackmore; Srisowmya Sanisetty; James R Perry; Matthew Beck; Mark G Lewis; William Rinaldi; Arup K Chakraborty; Pascal Poignard; Michel C Nussenzweig; Dennis R Burton
Journal:  Nature       Date:  2013-10-30       Impact factor: 49.962

10.  A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection.

Authors:  David Gardiner; Jay Lalezari; Eric Lawitz; Michael DiMicco; Rheem Ghalib; K Rajender Reddy; Kyong-Mi Chang; Mark Sulkowski; Steven O' Marro; Jeffrey Anderson; Bing He; Vikram Kansra; Fiona McPhee; Megan Wind-Rotolo; Dennis Grasela; Mark Selby; Alan J Korman; Israel Lowy
Journal:  PLoS One       Date:  2013-05-22       Impact factor: 3.240

View more
  114 in total

1.  Cell-Associated HIV-1 DNA and RNA Decay Dynamics During Early Combination Antiretroviral Therapy in HIV-1-Infected Infants.

Authors:  Priyanka Uprety; Ellen G Chadwick; Kaitlin Rainwater-Lovett; Carrie Ziemniak; Katherine Luzuriaga; Edmund V Capparelli; Gayane Yenokyan; Deborah Persaud
Journal:  Clin Infect Dis       Date:  2015-08-13       Impact factor: 9.079

2.  Establishment of a Novel Humanized Mouse Model To Investigate In Vivo Activation and Depletion of Patient-Derived HIV Latent Reservoirs.

Authors:  Nina C Flerin; Ariola Bardhi; Jian Hua Zheng; Maria Korom; Joy Folkvord; Colin Kovacs; Erika Benko; Ronald Truong; Talia Mota; Elizabeth Connick; R Brad Jones; Rebecca M Lynch; Harris Goldstein
Journal:  J Virol       Date:  2019-03-05       Impact factor: 5.103

Review 3.  Epidemiology, pathophysiology, and prevention of heart failure in people with HIV.

Authors:  Arjun Sinha; Matthew Feinstein
Journal:  Prog Cardiovasc Dis       Date:  2020-01-24       Impact factor: 8.194

4.  Dendritic Cells Enhance HIV Infection of Memory CD4(+) T Cells in Human Lymphoid Tissues.

Authors:  Angel L Reyes-Rodriguez; Morgan A Reuter; David McDonald
Journal:  AIDS Res Hum Retroviruses       Date:  2016-01-07       Impact factor: 2.205

5.  Anti-Human Immunodeficiency Virus Antibodies in the Cerebrospinal Fluid: Evidence of Early Treatment Impact on Central Nervous System Reservoir?

Authors:  Peter D Burbelo; Richard W Price; Lars Hagberg; Hiroyu Hatano; Serena Spudich; Steven G Deeks; Magnus Gisslén
Journal:  J Infect Dis       Date:  2018-03-13       Impact factor: 5.226

6.  HIV reservoirs as obstacles and opportunities for an HIV cure.

Authors:  Tae-Wook Chun; Susan Moir; Anthony S Fauci
Journal:  Nat Immunol       Date:  2015-06       Impact factor: 25.606

7.  Enigma of HIV-1 latent infection in astrocytes: an in-vitro study using protein kinase C agonist as a latency reversing agent.

Authors:  Ashok Chauhan
Journal:  Microbes Infect       Date:  2015-06-02       Impact factor: 2.700

Review 8.  Bispecific antibodies: Potential immunotherapies for HIV treatment.

Authors:  Giulia Fabozzi; Amarendra Pegu; Richard A Koup; Constantinos Petrovas
Journal:  Methods       Date:  2018-10-22       Impact factor: 3.608

9.  TLR3 agonist and CD40-targeting vaccination induces immune responses and reduces HIV-1 reservoirs.

Authors:  Liang Cheng; Qi Wang; Guangming Li; Riddhima Banga; Jianping Ma; Haisheng Yu; Fumihiko Yasui; Zheng Zhang; Giuseppe Pantaleo; Matthieu Perreau; Sandra Zurawski; Gerard Zurawski; Yves Levy; Lishan Su
Journal:  J Clin Invest       Date:  2018-08-27       Impact factor: 14.808

10.  Blocking type I interferon signaling enhances T cell recovery and reduces HIV-1 reservoirs.

Authors:  Liang Cheng; Jianping Ma; Jingyun Li; Dan Li; Guangming Li; Feng Li; Qing Zhang; Haisheng Yu; Fumihiko Yasui; Chaobaihui Ye; Li-Chung Tsao; Zhiyuan Hu; Lishan Su; Liguo Zhang
Journal:  J Clin Invest       Date:  2016-12-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.